English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Aims/Introduction  Patients with type 2 diabetes are known to show elevated serum levels of carbohydrate antigen 19‐9 ( CA 19‐9). The aim of the present study was to investigate the possible relationships of  CA 19‐9 with metabolic control, insulin resistance ( IR ), and pancreatic β‐cell function in patients with obesity and type 2 diabetes who underwent Roux‐En‐Y gastric bypass ( RYGB ).    Materials and Methods  The present study included 81 healthy volunteers, and 33 patients diagnosed with obesity and type 2 diabetes who underwent  RYGB . Anthropometry, serum levels of  CA 19‐9, glucose and lipid metabolic profiles, and serum insulin levels were determined at baseline and at 12 weeks after  RYGB .    Results  Changes in  CA 19‐9 were significantly and positively correlated with changes in fasting plasma glucose ( r  = 0.552,  P  = 0.001), 2‐h post‐challenge plasma glucose levels ( r  = 0.623,  P  = 0.000), glycated hemoglobin levels ( r  = 0.819,  P  = 0.000), glycated albumin levels ( r  = 0.711,  P  = 0.000), total cholesterol ( r  = 0.449,  P  = 0.009) and the Homeostasis Model of Assessment‐ IR  index ( r  = 0.407,  P  = 0.019). Furthermore, a multiple stepwise regression analysis showed that the changes in serum levels of  CA 19‐9 were independently and significantly associated with changes in glycated hemoglobin (β   = 0.598,  P  = 0.000), fasting plasma glucose (β   = 0.309,  P  = 0.000) and Homeostasis Model of Assessment‐ IR  (β   = 0.235,  P  = 0.010) after adjusting for confounding factors.    Conclusions   CA 19‐9 could be an effective indicator of  IR , and glycemic and lipid metabolism in patients with obesity and type 2 diabetes after rapid metabolic control by  RYGB . Additionally,  CA 19‐9 might be a marker with which to evaluate the short‐term effects of glycolipid toxicity on  IR  in these patients.

journal of diabetes investigation

Decreased serum  CA 19‐9 is associated with improvement of insulin resistance and metabolic control in patients with obesity and type 2 diabetes after Roux‐en‐Y gastric bypass